Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EPS (Basic) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EPS (Basic) for 7 consecutive years, with -$0.38 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 53.09% to -$0.38 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.43, a 29.77% increase, with the full-year FY2025 number at -$2.43, up 29.97% from a year prior.
  • EPS (Basic) was -$0.38 for Q4 2025 at Pliant Therapeutics, up from -$0.43 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.38 in Q4 2025 to a low of -$0.95 in Q3 2024.
  • A 5-year average of -$0.72 and a median of -$0.7 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 59.57% in 2021, then surged 54.74% in 2025.
  • Pliant Therapeutics' EPS (Basic) stood at -$0.68 in 2021, then decreased by 5.88% to -$0.72 in 2022, then rose by 4.17% to -$0.69 in 2023, then fell by 17.39% to -$0.81 in 2024, then soared by 53.09% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's EPS (Basic) are -$0.38 (Q4 2025), -$0.43 (Q3 2025), and -$0.7 (Q2 2025).